The Wire · All news

GLP-1 Vision Loss (Ozempic / Wegovy NAION)

Search Interest Spikes for Ozempic Blindness and Related Terms

Published Updated

By People's Justice

What happened

Google Trends data shows searches for 'ozempic blindness' rose 120% and 'ozempic lawsuit blindness' rose 130% week-over-week. Searches for 'tirzepatide side effects' also rose 170% in the same period, according to Google Trends.

Event date:

Source: trends.google.com

Related news

  1. GLP-1 Vision Loss (Ozempic / Wegovy NAION)

    Federal Lawsuits Over GLP-1 Drugs and Rare Vision Loss Top 200

    News outlets reported that over 200 federal lawsuits have been filed alleging GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro caused NAION, a rare and often permanent form of vision loss. Manufacturers reportedly dispute the claims, and plaintiffs allege they were not adequately warned of the risk.

    Source: yahoo.com

  2. GLP-1 Vision Loss (Ozempic / Wegovy NAION)

    Media Reports Detail Hundreds of GLP-1 Vision Loss Lawsuits; New Research Examines Eye Risks

    The New York Post reported that a man's claim of sudden, permanent blindness after using Ozempic is one of hundreds of lawsuits filed against GLP-1 drug makers alleging inadequate warning of vision loss risk. Separately, a Medical Economics roundup noted reporting that Wegovy may carry a higher risk of 'eye stroke' than other GLP-1 drugs, and a systematic review in the Canadian Journal of Ophthalmology examined a possible link between GLP-1 receptor agonist use and age-related macular degeneration.

    Source: news.google.com

  3. GLP-1 Vision Loss (Ozempic / Wegovy NAION)

    Hundreds of Lawsuits Filed Alleging GLP-1 Drugs Caused Vision Loss

    News reports from the New York Post and other outlets describe hundreds of lawsuits against GLP-1 drug makers, with plaintiffs alleging the drugs were not adequately labeled to warn of potential vision loss. A separate report notes Wegovy may carry a higher risk of 'eye stroke' than other GLP-1 drugs, and a new systematic review examined possible links between GLP-1 receptor agonist use and age-related macular degeneration.

    Source: news.google.com